Date	e:2022/11/	16	Youi
	ne: Qiuying D		
HE		reast cancer: a systema	with endocrine therapy in hormone receptor-positive, atic review and meta-analysis
In the relation to the relatio	ne interest of transparency, ted to the content of your miles whose interests may be ransparency and does not not it in the content of your miles whose interests may be ransparency and does not not it in the content of the content	we ask you to disclose all nanuscript. "Related" meansfected by the content of ecessarily indicate a bias. Is preferable that you do the author's relationship ities/interests should be asion, you should declare tion is not mentioned in the cort for the work reporte	ps/activities/interests as they relate to the <u>current</u> <u>defined broadly</u> . For example, if your manuscript pertains all relationships with manufacturers of antihypertensive
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: pas	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	

Consulting fees

X__None

5	Payment or honoraria for lectures, presentations,	XNone			
	speakers bureaus,				
	manuscript writing or				
	educational events				
6	Payment for expert	XNone			
	testimony				
7	Support for attending meetings and/or travel	XNone			
8	Patents planned, issued or	XNone			
	pending				
9	Participation on a Data Safety Monitoring Board or	XNone			
	Advisory Board				
10	in other board, society,	XNone			
	committee or advocacy				
	group, paid or unpaid	V N			
11	Stock or stock options	XNone			
12	Descipt of accions and	V. Nana			
12	Receipt of equipment, materials, drugs, medical	XNone			
	writing, gifts or other				
	services				
13	Other financial or non-	X None			
	financial interests				
Plea	Please summarize the above conflict of interest in the following box:				

No	one		

Date:	2022/11/16Yo	uı
Name:	Yongling Wang	
Manuscript Title	: CDK4/6 inhibitors combined with endocrine therapy in hormone receptor-positive,	
HER2-negativ	e, advanced breast cancer: a systematic review and meta-analysis	
Manuscript num	ber (if known):	
related to the coparties whose in	f transparency, we ask you to disclose all relationships/activities/interests listed below that are intent of your manuscript. "Related" means any relation with for-profit or not-for-profit third terests may be affected by the content of the manuscript. Disclosure represents a commitment and does not necessarily indicate a bias. If you are in doubt about whether to list a	

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	X_None	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5 Payment or honoraria fo	rXNone			
lectures, presentations,				
speakers bureaus, manuscript writing or				
educational events				
6 Payment for expert	X None			
testimony				
7 Support for attending meetings and/or travel	XNone			
8 Patents planned, issued	or X_None			
pending				
9 Participation on a Data	X None			
Safety Monitoring Board				
Advisory Board				
10 Leadership or fiduciary re	oleXNone			
in other board, society,				
committee or advocacy group, paid or unpaid				
11 Stock or stock options	XNone			
10 0 11 6				
12 Receipt of equipment,	XNone			
materials, drugs, medica writing, gifts or other	·			
services				
13 Other financial or non-	XNone			
financial interests				
Please summarize the above conflict of interest in the following box:				

None		

Date	e: 2022/11/	16		Your
	ne:Mingjuan			_
Man HEI	uscript Title: CDK4/6 R2-negative, advanced b	inhibitors combined wreast cancer: a systema	rith endocrine therapy in hormone receptor-posit	ive,
relat parti to tr	ted to the content of your nies whose interests may be	nanuscript. "Related" mea affected by the content o ecessarily indicate a bias.	relationships/activities/interests listed below that are ins any relation with for-profit or not-for-profit third f the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.	
	following questions apply t uscript only.	o the author's relationshi	ps/activities/interests as they relate to the <u>current</u>	
to th	• •	nsion, you should declare	defined broadly. For example, if your manuscript perta all relationships with manufacturers of antihypertension he manuscript.	
	em #1 below, report all sup time frame for disclosure is	•	d in this manuscript without time limit. For all other ite	ems,
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
		Time frame: Since the initia	al planning of the work	
1	All support for the present	XNone		
	manuscript (e.g., funding, provision of study materials,			

Time frame: past 36 months

X__None

X_None

X__None

medical writing, article processing charges, etc.)

No time limit for this item.

Grants or contracts from

in item #1 above).

Consulting fees

Royalties or licenses

any entity (if not indicated

2

3

5	Payment or honoraria for	XNone			
	lectures, presentations, speakers bureaus,				
	manuscript writing or				
	educational events				
6	Payment for expert	XNone			
	testimony				
7	Support for attending meetings and/or travel	XNone			
8	Patents planned, issued or	XNone			
	pending				
	5	V N			
9	Participation on a Data Safety Monitoring Board or	XNone			
	Advisory Board				
10	Leadership or fiduciary role	X None			
	in other board, society,				
	committee or advocacy group, paid or unpaid				
11	Stock or stock options	XNone			
12	Receipt of equipment,	XNone			
	materials, drugs, medical writing, gifts or other				
	services				
13	Other financial or non-	X None			
	financial interests				
Plea	Please summarize the above conflict of interest in the following box:				

None		

Date:	2022/11/16	Your
Name:	Hongfeng Chen	
Manuscript Title:_	CDK4/6 inhibitors combined with endocrine therapy in hormone recepto	r-positive,
HER2-negative,	, advanced breast cancer: a systematic review and meta-analysis	
Manuscript numb	per (if known):	
related to the con	transparency, we ask you to disclose all relationships/activities/interests listed below to tent of your manuscript. "Related" means any relation with for-profit or not-for-profit terests may be affected by the content of the manuscript. Disclosure represents a comm	third
•	and does not necessarily indicate a bias. If you are in doubt about whether to list a	ii ciii cii c
•	vity/interest, it is preferable that you do so.	

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	X_None	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for lectures, presentations,	XNone					
	speakers bureaus,						
	manuscript writing or						
	educational events						
6	Payment for expert testimony	XNone					
_							
7	Support for attending meetings and/or travel	XNone					
8	Patents planned, issued or pending	XNone					
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone					
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone					
11	Stock or stock options	XNone					
12	Receipt of equipment, materials, drugs, medical	XNone					
	writing, gifts or other						
10	services	V N					
13	Other financial or non-	XNone					
	financial interests						
Plea	Please summarize the above conflict of interest in the following box:						

None			